Conjugate of an antibody against CCR5 and an antifusogenic peptide
The current invention is related to a conjugate comprising one or more antifusogenic peptides and an anti-CCR5 antibody (mAb CCR5) characterized in that one to eight antifusogenic peptides are each conjugated to one terminus of the heavy and/or light chains of the anti-CCR5 antibody and to the pharmaceutical use of the conjugate.
1. A conjugate comprising an anti-CCR5 antibody (mAb CCR5) comprising two heavy chains and two light chains, having termini comprising an N-terminus and a C-terminus, wherein two or four of said N-terminus or said C-terminus are conjugated with an antifusogenic peptide; wherein said anti-CCR5 antibody comprises a variable heavy chain domain and a variable light chain domain, wherein said variable heavy chain domain consists of an immunoglobulin framework and a CDR3 region selected from the group consisting of heavy chain CDR3 sequences SEQ ID NOS:16 and 17; a CDR2 region selected from the group consisting of heavy chain CDR2 sequences SEQ ID NOS:13, 14, and 15; and a CDR1 region selected from the group consisting of heavy chain CDR1 sequences SEQ ID NOS:9, 10, 11, and 12; and wherein said variable light chain domain consists of an immunoglobulin framework and a CDR1 region selected from SEQ ID NOS:18, 19, and 20; a CDR2 region selected from SEQ ID NOS:21, 22, and 23; and a CDR3 region selected from SEQ ID NOS:24 and 25.
2. The conjugate of claim 1 , wherein said antifusogenic peptide has a sequence selected from the group consisting of SEQ ID NOS:29 to 35.
3. A conjugate comprising an anti-CCR5 antibody (mAb CCR5) comprising two heavy chains and two light chains, having termini comprising an N-terminus and a C-terminus, wherein two or four of said N-terminus or said C-terminus are conjugated with an antifusogenic peptide; wherein said anti-CCR5 antibody is of IgG4 subclass, or is of IgG1 or IgG2 subclass with a mutation in amino acid 5228, L234, L235, and/or D265, and/or contains the PVA236 mutation.
4. A conjugate according to claim 3 , wherein said anti-CCR5 antibody of IgG4 subclass has the mutation S228P and said anti-CCR5 antibody of IgG1 subclass has the mutations L234A and L235A.
5. A pharmaceutical composition, comprising an effective amount of a conjugate of claim 1 , together with a pharmaceutically acceptable excipient or carrier.